Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Eli Lilly and CompanyNYSE: LLY

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 85.8%

Gross margin was 85.8% in Q2 FY2026, up 1.5 pp from a year earlier. On a trailing-twelve-month basis it was 83.4%, up 0.8 pp year over year. Over 3 fiscal years it widened by 6.3 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
85.8%+3.8 pp QoQ
Last fiscal yearDec 2025
83.0%+1.7 pp YoY
LTMJun 2026
83.4%+0.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.5 pp——
1 year+1.7 pp——
3 years+6.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
83.0%
Year-over-year change
+1.7pp

Gross Margin vs competitors

How LLY compares with its peers on the latest reported figures

  • LLY's LTM Jun 2026 gross margin of 83.4% is the highest of the 10 companies compared; the peer median is 74.4%.
  • Its year-over-year change of +0.8 pp is the 5th highest of 10, against a peer median of +0.7 pp.
  • Over three fiscal years its change of +6.3 pp compares with a peer median of +1.3 pp.
LLY Competitors Peer median
Gross Margin for LLY and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202683.4% +0.8 pp+6.3 pp
NVONovo Nordisk A/SLTM Jun 202680.6% -3.3 pp-2.9 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
ABBVAbbVie Inc.LTM Sep 202676.3% +6.5 pp+0.2 pp
MRKMerck & Co., Inc.LTM Jun 202675.4% -0.1 pp+1.3 pp
NVSNovartis AGLTM Jun 202674.4% -1.8 pp+1.7 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
SNYSanofiLTM Jun 202673.0% +1.4 pp+1.4 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
JNJJohnson & JohnsonLTM Sep 202668.8% +0.7 pp-1.4 pp
Peer median (excluding LLY) 74.4%+0.7 pp+1.3 pp

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.32B28.54B34.12B45.04B65.18B
Cost of Revenue7.31B6.63B7.08B8.42B11.05B
Gross Profit21.01B21.91B27.04B36.63B54.13B
Gross Margin74.2%76.8%79.2%81.3%83.0%
Research & Development6.93B7.19B9.31B10.99B13.34B
Selling, General & Admin6.14B6.07B6.94B8.59B11.09B
Operating Expenses13.07B13.26B16.25B19.59B24.43B
Depreciation & Amortization1.55B1.52B1.53B1.77B2B
EBITDA8.04B8.66B8.57B18.81B31.69B
EBITDA Margin28.4%30.3%25.1%41.8%48.6%
Operating Income7.93B8.65B10.79B17.04B29.7B
Operating Margin28.0%30.3%31.6%37.8%45.6%
Interest Income25.4M62.8M173.6M175.2M153.3M
Interest Expense339.8M331.6M485.9M780.6M795.3M
Other Income / Expenses(1.78B)(1.85B)(4.23B)(4.36B)(3.97B)
Income Before Tax6.16B6.81B6.55B12.68B25.73B
Pre-Tax Margin21.7%23.8%19.2%28.2%39.5%
Income Tax Expense573.8M561.6M1.31B2.09B5.09B
Net Income5.58B6.24B5.24B10.59B20.64B
Net Margin19.7%21.9%15.4%23.5%31.7%
EPS (Basic)5.856.575.8311.7623.07
EPS (Diluted)5.856.575.8011.7122.95
Weighted Avg Shares953.65M950.18M899.38M900.61M898M
Weighted Avg Shares (Diluted)953.65M950.18M903.28M904.06M898M

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.